BDBM312465 3-[3-(3-Cyclopropyl-[1,2,4]thiadiazol-5-yl)-4,5,6,7-tetrahydro-benzo[b]thiophen-2-ylcarbamoyl]-bicyclo[2.2.2]oct-2-ene-2-carboxylic acid::US9604977, Example 211

SMILES: OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCCc2c1-c1nc(ns1)C1CC1

InChI Key: InChIKey=MVWIQVFNQYUERQ-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 312465   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Fatty acid-binding protein 5 (FABP5) (Homo sapiens (Human))	BDBM312465 (3-[3-(3-Cyclopropyl-[1,2,4]thiadiazol-5-yl)-4,5,6,...) Show SMILES OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCCc2c1-c1nc(ns1)C1CC1 |t:3,(1.79,-5.59,;3.28,-5.2,;4.36,-6.28,;3.67,-3.71,;2.9,-2.37,;3.67,-1.04,;5.21,-1.04,;5.98,-2.37,;5.21,-3.71,;3.88,-2.94,;4.97,-1.85,;1.36,-2.37,;.59,-3.71,;.59,-1.04,;-.95,-1.04,;-1.85,-2.29,;-3.32,-1.81,;-4.65,-2.58,;-5.98,-1.81,;-5.98,-.27,;-4.65,.5,;-3.32,-.27,;-1.85,.2,;-1.45,1.69,;.01,2.17,;.01,3.71,;-1.45,4.18,;-2.36,2.94,;1.1,4.8,;2.59,5.2,;1.5,6.28,)| Show InChI InChI=1S/C23H25N3O3S2/c27-20(16-11-5-7-12(8-6-11)17(16)23(28)29)25-21-18(14-3-1-2-4-15(14)30-21)22-24-19(26-31-22)13-9-10-13/h11-13H,1-10H2,(H,25,27)(H,28,29)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	34	n/a	n/a	n/a	n/a	n/a	n/a
Hoffman-La Roche Inc. US Patent					Assay Description Compounds were profiled for activity against human FABP4 (huFABP4) and/or human FABP5 (huFABP5) in Terbium (Tb) time resolved-fluorescence energy tra...				US Patent US9604977 (2017) BindingDB Entry DOI: 10.7270/Q2FX7CJB
					More data for this Ligand-Target Pair
Fatty acid-binding protein 4 (FABP4) (Homo sapiens (Human))	BDBM312465 (3-[3-(3-Cyclopropyl-[1,2,4]thiadiazol-5-yl)-4,5,6,...) Show SMILES OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCCc2c1-c1nc(ns1)C1CC1 |t:3,(1.79,-5.59,;3.28,-5.2,;4.36,-6.28,;3.67,-3.71,;2.9,-2.37,;3.67,-1.04,;5.21,-1.04,;5.98,-2.37,;5.21,-3.71,;3.88,-2.94,;4.97,-1.85,;1.36,-2.37,;.59,-3.71,;.59,-1.04,;-.95,-1.04,;-1.85,-2.29,;-3.32,-1.81,;-4.65,-2.58,;-5.98,-1.81,;-5.98,-.27,;-4.65,.5,;-3.32,-.27,;-1.85,.2,;-1.45,1.69,;.01,2.17,;.01,3.71,;-1.45,4.18,;-2.36,2.94,;1.1,4.8,;2.59,5.2,;1.5,6.28,)| Show InChI InChI=1S/C23H25N3O3S2/c27-20(16-11-5-7-12(8-6-11)17(16)23(28)29)25-21-18(14-3-1-2-4-15(14)30-21)22-24-19(26-31-22)13-9-10-13/h11-13H,1-10H2,(H,25,27)(H,28,29)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
Hoffman-La Roche Inc. US Patent					Assay Description Compounds were profiled for activity against human FABP4 (huFABP4) and/or human FABP5 (huFABP5) in Terbium (Tb) time resolved-fluorescence energy tra...				US Patent US9604977 (2017) BindingDB Entry DOI: 10.7270/Q2FX7CJB
					More data for this Ligand-Target Pair